News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Kalkine Media Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
S&CO Inc. has acquired a new stake in AstraZeneca Plc, purchasing 37,990 shares valued at approximately $7.1 million during the second quarter. Institutional investors now collectively own 20.35% of AstraZeneca's stock. Analysts maintain a "Moderate Buy" rating for AstraZeneca, with an average price target …
AstraZeneca PLC (AZN) shares fell 2.12% to £114.60 on Friday, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed significantly below its 52-week high, which was achieved earlier in the year.
Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …
Wealthcare Advisory Partners LLC acquired 12,112 shares of AstraZeneca Plc, valued at approximately $2.3 million, in the second quarter. This move is part of a broader trend of institutional investors increasing their holdings in the pharmaceutical company, which now has 20.35% institutional ownership. AstraZeneca …
AstraZeneca PLC (AZN) shares fell 1.20% to £117.02 on Wednesday, underperforming the broader market as the FTSE 100 Index (UKX) also dropped. The company's stock closed 25.62% below its 52-week high.
One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. …
This article provides a compilation of recent news and updates concerning AstraZeneca PLC (AZN). Key topics include options market movements, hedge fund bullishness, and reports of potential acquisition talks with Bristol Myers Squibb. It also covers related pharmaceutical news such as Merck's performance and …
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …
Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is …
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug …
This article details VELA LARGE CAP PLUS FUND's holding history for AstraZeneca PLC (AZN). As of March 31, 2026, the fund held 4,854 shares of AZN, valued at $957,310, constituting 1.64% of its portfolio. The initial purchase occurred in Q1 2026 at an average …
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate …
FNY Investment Advisers LLC significantly reduced its stake in AstraZeneca Plc by 97.2% in Q2 2026, selling 7,050 shares and retaining 200. This comes despite AstraZeneca beating EPS estimates with $2.63, though its revenue of $15.38 billion slightly missed forecasts. The stock currently holds …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical …
Parallel Advisors LLC has acquired a new position in AstraZeneca Plc, purchasing 8,718 shares valued at approximately $1.72 million in the first quarter. This comes as institutional investors collectively own 20.35% of AstraZeneca, and analysts maintain a "Moderate Buy" consensus rating with an average …
Professional Advisory Services Inc. recently acquired 161,624 shares of AstraZeneca Plc (NYSE:AZN) for approximately $30.2 million, making it their seventh-largest holding. AstraZeneca reported strong quarterly earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating for the stock. The company's financial performance and …
AstraZeneca PLC's average 12-month price target has been increased to $216.47, up from $215.03, according to 26 analysts. This updated target suggests a potential upside of approximately 34% based on the August 6 closing price. The consensus rating from 31 analysts remains a "Buy," …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AstraZeneca (LSE:AZN) is back in focus after a senior source told Reuters that there are no ongoing merger discussions with Bristol Myers Squibb, reversing earlier …
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%On holiday in Devon this summer, Charles Hall felt a familiar sinking feeling. The most senior analyst at City stockbroker Peel Hunt had just read that AstraZeneca held talks with US pharmaceutical giant Bristol Myers Squibb about a potential merger. It reignited concerns that …
Search by ticker symbol or company name and select a result to open its chart.